Newsletter

Subscribe and receive updates on this company

Text STOCKS to 72727 for mobile alerts

We are excited to present Bayer A.G. (OTC: BAYZF).

Full DD Report for BAYZF

You must become a subscriber to view this report.


Recent News from (OTC: BAYZF)

The Ongoing Loxo Thesis, Part 1: Loxo's Rising Star
Note: Subscribers to the Total Pharma Tracker got an early look at this article, as well as access exclusive notes offering my opinions on the end game for these companies. You can try for free and join this conversation! Loxo Oncology ( LOXO ) is one of those companies that biotech in...
Source: SeekingAlpha
Date: May, 10 2018 02:44
Institutional Top Ideas Series: Orbimed Advisors
In the last entry of this series, we took a look at top ideas from Baker Bros. Advisors (whose performance has been struggling of late but they've built up a stellar reputation and track record of long term outperformance). Going forward, I hope to continue to delve into the portfolios of...
Source: SeekingAlpha
Date: May, 04 2018 03:18
Bayer's (BAYZF) CEO Werner Baumann on Q1 2018 Results - Earnings Call Transcript
Bayer AG (BAYZF) Q1 2018 Earnings Conference Call May 3, 2018 8:00 AM ET Executives Oliver Maier – Head of Investor Relations Werner Baumann – Chief Executive Officer Johannes Dietsch – Chief Financial Officer Dieter Weinand – Pharmaceuticals Heiko...
Source: SeekingAlpha
Date: May, 03 2018 22:45
Bayer A.G. 2018 Q1 - Results - Earnings Call Slides
The following slide deck was published by Bayer A.G. in conjunction with their 2018 Q1 earnings Read more ...
Source: SeekingAlpha
Date: May, 03 2018 14:00
Bayer trades flat even after cutting full-year earnings guidance
Bayer ( OTCPK:BAYRY , OTCPK:BAYZF ) shares are little changed after the company says it expects adjusted EBITDA to decline by a low single-digit percentage to less than €35B ($42B) for FY 2018, rather than coming in flat as previously forecast. More news on: Bayer A.G. ADR, Bayer...
Source: SeekingAlpha
Date: May, 03 2018 09:42
Bayer A.G. beats by Euro0.20, misses on revenue
Bayer A.G. ( OTCPK:BAYZF ): Q1 EPS of €2.28 beats by €0.20 . Revenue of €9.14B (-5.6% Y/Y) misses by €130M . Press Release More news on: Bayer A.G., Bayer A.G. ADR, Earnings news and commentary,
Source: SeekingAlpha
Date: May, 03 2018 06:30
Oakmark International Fund: Q1 2018
Oakmark International Fund – Investor Class Average Annual Total Returns (03/31/18) Since Inception (09/30/92) 10.17% 10–year 7.91% 5–year 8.74% 1–year 15.29% 3–month -2.77% Gross Expense Ratio as of 09/30/17 was 1.00% Net Expense Ratio as of 09/30/...
Source: SeekingAlpha
Date: April, 23 2018 02:03
Oakmark Global Fund: Q1 2018
Oakmark Global Fund – Investor Class Average Annual Total Returns (03/31/18) Since Inception (08/04/99) 10.48% 10–year 7.09% 5–year 9.71% 1–year 15.08% 3–month -2.57% Gross Expense Ratio as of 09/30/17 was 1.21% Net Expense Ratio as of 09/30/17 wa...
Source: SeekingAlpha
Date: April, 23 2018 01:57
The U.S. Approves Bayer And Monsanto's Merger
The proposed merger between Bayer AG (BAYZF) and Monsanto (MON) received good news from the U.S. Department of Justice last week as the DOJ appears to be blessing the combination of the two companies into one agricultural giant. In the U.S. the regulators were concerned that a dominant company...
Source: SeekingAlpha
Date: April, 17 2018 06:00
Verastem: A Solid Player On A Crowded Field
My investment thesis is narrow, I focus on niche players in biotech. I have developed my bias over years of investments in companies in different situations. While I love to make the right investment, getting it wrong has provided me with the more valuable education that has enabled me to pick...
Source: SeekingAlpha
Date: April, 12 2018 10:22

 


About Bayer A.G. (OTC: BAYZF)

Logo for Bayer A.G. (OTC: BAYZF)

Bayer is a global enterprise with core competencies in the fields of health care, nutrition and high tech materials. At the same time Bayer creates value through innovation, growth and improved earning power. Bayer HealthCare AG researches, develops, manufactures and markets innovative products for disease prevention, diagnosis and treatment. Bayer CropScience AG is a global leader in crop protection and non agricultural pest control. Bayer MaterialScience AG is a renowned supplier of high performance materials and innovative system solutions used in a wide range of products for everyday life. The Group is committed to the principles of sustainable development and acknowledges and accepts its role as a socially and ethically responsible corporate citizen, economy, ecology and social responsibility are corporate policy objectives of equal rank.

 

 

 

Current Management

  • Dr. Marijn Dekkers / CEO
  • Werner Wenning / CFO
  • Martin Eisenhauer / Securities Counsel
  • Peter Dahlhoff / IR

Current Share Structure

  • Market Cap: $98,133,895,426 - 05/11/2018
  • Issue and Outstanding: 826,947,800 - 03/31/2011

 



Daily Technical Chart for (OTC: BAYZF)

Daily Technical Chart for (OTC: BAYZF)


Stay tuned for daily updates and more on (OTC: BAYZF)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (OTC: BAYZF)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

OTC Report
@OTCReporter

 

 


Disclaimer: OTC Report publishes reports providing information on selected companies. OTC Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. OTC Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in BAYZF is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. OTC Report has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. OTC Report does not own any shares of BAYZF and does not buy, sell, or trade any shares of BAYZF. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by OTC Report. All rights reserved. Our Full Disclaimer: http://otc.report/disclaimer/